Cargando…

Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis

Bronchiectasis is an airway disease characterized by thickening of the bronchial wall, chronic inflammation , and destruction of affected bronchi. Underlying etiologies include severe pulmonary infection and cystic fibrosis (CF); however, in a substantial number of patients with non-CF-related bronc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergin, David A, Hurley, Killian, Mehta, Adwait, Cox, Stephen, Ryan, Dorothy, O’Neill, Shane J, Reeves, Emer P, McElvaney, Noel G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576001/
https://www.ncbi.nlm.nih.gov/pubmed/23426081
http://dx.doi.org/10.2147/JIR.S40081
_version_ 1782259798669000704
author Bergin, David A
Hurley, Killian
Mehta, Adwait
Cox, Stephen
Ryan, Dorothy
O’Neill, Shane J
Reeves, Emer P
McElvaney, Noel G
author_facet Bergin, David A
Hurley, Killian
Mehta, Adwait
Cox, Stephen
Ryan, Dorothy
O’Neill, Shane J
Reeves, Emer P
McElvaney, Noel G
author_sort Bergin, David A
collection PubMed
description Bronchiectasis is an airway disease characterized by thickening of the bronchial wall, chronic inflammation , and destruction of affected bronchi. Underlying etiologies include severe pulmonary infection and cystic fibrosis (CF); however, in a substantial number of patients with non-CF-related bronchiectasis (NCFB), no cause is found. The increasing armamentarium of therapies now available to combat disease in CF is in stark contrast to the limited tools employed in NCFB. Our study aimed to evaluate similarities and differences in airway inflammatory markers in patients with NCFB and CF, and to suggest potential common treatment options. The results of this study show that NCFB bronchoalveolar lavage fluid samples possessed significantly increased NE activity and elevated levels of matrix metalloproteinases 2 (MMP-2) and MMP-9 compared to healthy controls (P < 0.01); however, the levels detected were lower than in CF (P < 0.01). Interleukin-8 (IL-8) concentrations were significantly elevated in NCFB and CF compared to controls (P < 0.05), but in contrast, negligible levels of IL-18 were detected in both NCFB and CF. Analogous concentrations of IL-10 and IL-4 measured in NCFB and CF were statistically elevated above the healthy control values (P < 0.05 and P < 0.01, respectively). These results indicate high levels of important proinflammatory markers in both NCFB and CF and support the use of appropriate anti-inflammatory therapies already employed in the treatment of CF bronchiectasis in NCFB.
format Online
Article
Text
id pubmed-3576001
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35760012013-02-20 Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis Bergin, David A Hurley, Killian Mehta, Adwait Cox, Stephen Ryan, Dorothy O’Neill, Shane J Reeves, Emer P McElvaney, Noel G J Inflamm Res Original Research Bronchiectasis is an airway disease characterized by thickening of the bronchial wall, chronic inflammation , and destruction of affected bronchi. Underlying etiologies include severe pulmonary infection and cystic fibrosis (CF); however, in a substantial number of patients with non-CF-related bronchiectasis (NCFB), no cause is found. The increasing armamentarium of therapies now available to combat disease in CF is in stark contrast to the limited tools employed in NCFB. Our study aimed to evaluate similarities and differences in airway inflammatory markers in patients with NCFB and CF, and to suggest potential common treatment options. The results of this study show that NCFB bronchoalveolar lavage fluid samples possessed significantly increased NE activity and elevated levels of matrix metalloproteinases 2 (MMP-2) and MMP-9 compared to healthy controls (P < 0.01); however, the levels detected were lower than in CF (P < 0.01). Interleukin-8 (IL-8) concentrations were significantly elevated in NCFB and CF compared to controls (P < 0.05), but in contrast, negligible levels of IL-18 were detected in both NCFB and CF. Analogous concentrations of IL-10 and IL-4 measured in NCFB and CF were statistically elevated above the healthy control values (P < 0.05 and P < 0.01, respectively). These results indicate high levels of important proinflammatory markers in both NCFB and CF and support the use of appropriate anti-inflammatory therapies already employed in the treatment of CF bronchiectasis in NCFB. Dove Medical Press 2013-01-23 /pmc/articles/PMC3576001/ /pubmed/23426081 http://dx.doi.org/10.2147/JIR.S40081 Text en © 2013 Bergin et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Bergin, David A
Hurley, Killian
Mehta, Adwait
Cox, Stephen
Ryan, Dorothy
O’Neill, Shane J
Reeves, Emer P
McElvaney, Noel G
Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title_full Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title_fullStr Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title_full_unstemmed Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title_short Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
title_sort airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576001/
https://www.ncbi.nlm.nih.gov/pubmed/23426081
http://dx.doi.org/10.2147/JIR.S40081
work_keys_str_mv AT bergindavida airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT hurleykillian airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT mehtaadwait airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT coxstephen airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT ryandorothy airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT oneillshanej airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT reevesemerp airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis
AT mcelvaneynoelg airwayinflammatorymarkersinindividualswithcysticfibrosisandnoncysticfibrosisbronchiectasis